Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis

Eiko Nishi, Hideto Kameda, Hiroe Ogawa, Hayato Nagasawa, Hirofumi Takei, Ayumi Okuyama, Takahiko Kurasawa, Tsuneo Kondo, Koji Nishimura, Yuichiro Shirai, Ryota Sakai, Tatsuya Ito, Tsutomu Takeuchi, Koichi Amano

研究成果: Article査読

11 被引用数 (Scopus)


Objective: We investigated the efficacy of a high-dose intermittent dosing treatment method (weekly mizoribine pulse therapy) conceived in the hope of achieving better efficacy by increasing the peak blood levels of mizoribine in patients with refractory lupus nephritis. Methods: Seventeen patients with lupus nephritis who had been resistant to corticosteroid and immunosuppressant therapy received weekly mizoribine pulse therapy. Mizoribine (350 mg) was administered three times at 12 h intervals over 2 consecutive days (700 mg for day 1 and 350 mg for day 2), followed by a washout period from day 3 to day 7. Results: This therapeutic strategy enabled the peak blood levels of mizoribine to be increased to more than 3 μg/mL in most of the patients. Although SLEDAI, anti-ds-DNA antibody titer, CH-50, and serum albumin level did not significantly improve, urinary protein levels decreased, and it was possible to taper the dose of concomitant steroids. Using our definition of clinical response, 10 of the 17 patients were responders and 4 of them were nonresponders. The average peak serum mizoribine concentration of the responders was as high as 3.5 μg/mL. Elevation of serum liver enzymes was seen in 1 patient, and hyperuricemia occurred in 4 cases, but none of these adverse events were serious. Conclusion: Intermittent administration of mizoribine can increase blood levels and may be effective for refractory lupus nephritis.

ジャーナルModern rheumatology
出版ステータスPublished - 2013 1月

ASJC Scopus subject areas

  • リウマチ学


「Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。